Clinical trials: sponsored by Sanofi
Bullous Pemphigoid (BP), Cold Agglutinin Disease (CAD)
Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated Disorders
Prospective, double-blind, randomized, placebo-controlled First-In-Human study with four sub-parts: Part A, a single ascending dose study (SAD) in normal human volunteers (NHVs), Part B, a multiple ascending dose study (MAD) in…
- Conditions
- Bullous Pemphigoid (BP), Cold Agglutinin Disease (CAD), Warm Autoimmune Hemolytic Anemia (WAIHA), End-stage Renal Disease (ESRD)
- Trial name
- BIVV009-01 (NCT02502903)
- Testing
- BIV009
- Where
- Austria
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Bioverativ, a Sanofi company
Progressive Multiple Sclerosis
A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Primary Objective: To assess the safety and tolerability of GZ402668 after a single subcutaneous (SC) dose in men and women with progressive multiple sclerosis.
- Trial name
- NCT02977533
- Testing
- GZ402668, Acyclovir
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Sanofi
Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
Effect of Venglustat in Patients With Renal Impairment
Primary Objective: To study the effect of mild, moderate and severe renal impairment on the pharmacokinetics (PK) of Venglustat following a single dose.
- Trial name
- NCT03687554
- Testing
- Venglustat GZ/SAR402671
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Influenza, Flu
Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years
This was a blind-observer, monocenter, randomized, comparative, Phase IV study designed to evaluate the immunogenicity and safety of the Sanofi Pasteur Shenzhen Trivalent Influenza Vaccine (SP Shz TIV) versus the Trivalent…
- Trial name
- NCT03344029
- Testing
- SP Shz TIV, Hualan TIV
- Where
- China
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin
Primary Objective: To demonstrate noninferiority of Toujeo versus "standard of care" basal insulin therapy measured as glycosylated hemoglobin (HbA1c) change Secondary Objectives: To demonstrate superiority of Toujeo versus…
- Trial name
- Reach-Control (NCT02967224)
- Testing
- insulin glargine (U300), insulin glargine (U100), NPH insulin
- Where
- 128 sites in Brazil, France and 5 more
- Volunteers
- 705 people
- Sponsor
- Sanofi
Food Allergy
A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients
Primary Objective: To assess tolerability and safety of SAR439794 [peanut extract (PE) sublingual immunotherapy (SLIT) adjuvanted with Glucopyranosyl Lipid A (GLA)] after repeated sublingual (SL) daily administration in peanut…
- Trial name
- NCT03463135
- Testing
- Glucopyranosyl Lipid A (GLA), Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)
- Where
- 16 sites in United States
- Volunteers
- 27 people
- Sponsor
- Sanofi
Lymphoma
Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia
Primary Objective: To evaluate safety of rasburicase in pediatric patients with NHL and AL Secondary Objective: To assess efficacy of rasburicase for prevention and treatment of hyperuricemia
- Trial name
- RAISE (NCT04349306)
- Testing
- RASBURICASE SR29142
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sanofi
Pharyngitis
Efficacy and Safety Study of New Ambroxol Hardboiled Lozenges in Acute Pharyngitis
Primary Objective: To assess the efficacy of the new hard boiled Ambroxol lozenges 20 mg for the relief of sore throat pain in patients with acute pharyngitis.
- Trial name
- DELICIOUS (NCT03583658)
- Testing
- ambroxol BIH1526
- Where
- South Africa
- Volunteers
- 390 people
- Sponsor
- Sanofi
Plasma Cell Myeloma
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma
Primary Objective: Part A: To evaluate the safety of SAR650984 (isatuximab) in patients with relapsed/refractory multiple myeloma (RRMM).
- Trial name
- NCT02514668
- Testing
- Isatuximab
- Where
- 18 sites in United States, Czechia and 1 more
- Volunteers
- 55 people
- Sponsor
- Sanofi
Healthy Volunteers (Rabies Immunization)
Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year
The primary objective of the study is to demonstrate that a short intramuscular (IM) pre-exposure prophylaxis (PrEP) regimen is non-inferior to the reference IM PrEP regimen in terms of seroconversion rate.
- Trial name
- VAJ00001 (NCT03700242)
- Testing
- HDCV, PVRV
- Where
- 2 sites in Philippines
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rhinitis Seasonal
Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants
Primary Objectives: To demonstrate that the aggravation of seasonal allergic rhinitis symptoms in the presence of pollutants is observed using an Environmental Exposure Unit.
- Trial name
- FEXPOLSAR (NCT03664882)
- Testing
- Fexofenadine M016455
- Where
- Canada
- Volunteers
- 240 people
- Sponsor
- Sanofi
Pertussis
Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines
The purpose of this cohort study is to determine vaccine-specific rates of pertussis disease during the period of the study, among Wisconsin residents younger than 60 months of age (the Surveillance Population), and to…
- Trial name
- NCT01129362
- Testing
- Pentacel® (DTaP-IPV/Hib), Other Pertussis Vaccines
- Where
- 2 sites in United States
- Volunteers
- 1,195 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Type 2 Diabetes Mellitus
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine by demonstrating change in glycosylated hemoglobin (HbA1c).
- Trial name
- NCT03529123
- Testing
- INSULIN GLARGINE/LIXISENATIDE (HOE901/AVE0010), INSULIN GLARGINE (HOE901), Metformin
- Where
- 13 sites in India
- Volunteers
- 247 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus
Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients
Primary Objective: To assess the safety of SAR341402 and NovoLog® when used in external insulin pumps in terms of the number of patients with infusion set occlusions.
- Trial name
- NCT03436498
- Testing
- Insulin aspart SAR341402, Insulin aspart
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period
Primary Objectives: Main study: To assess in overweight to obese subjects and type 2 diabetes mellitus (T2DM) patients not requiring anti-diabetic pharmacotherapy the safety and tolerability of 3 different dose escalation…
- Trial name
- NCT03414736
- Testing
- SAR425899
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sanofi
Alport Syndrome
A Study of RG-012 in Subjects With Alport Syndrome
This is a Phase 1, open-label, multi-center study of the safety, pharmacodynamics, and pharmacokinetics of RG-012 administered to subjects with Alport syndrome.
- Trial name
- NCT03373786
- Testing
- RG012
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- Genzyme, a Sanofi Company
Coronary Artery Disease
An Open-label, Non-comparative Study to Document the Tolerability to Ramipril in Patients With at Least One High Risk for Developing a Major Cardiovascular Event
Primary Objective: To document the tolerability of patients receiving study medication at 12-week of therapy in terms of the scoring system assessed by the investigator.
- Trial name
- HOPETips (NCT03099213)
- Testing
- RAMIPRIL HOE498
- Where
- Indonesia
- Volunteers
- 179 people
- Sponsor
- Sanofi
Diabetes
Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.
Primary Objective: Assess effectiveness of insulin glargine (U300) in achieving glycemic goal measured by hemoglobin A1c (HbA1c).
- Trial name
- ATOS (NCT03703869)
- Testing
- Insulin glargine (U300)
- Where
- 388 sites in Colombia, Egypt and 16 more
- Volunteers
- 4,589 people
- Sponsor
- Sanofi
End-stage Renal Disease
A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant
Primary Objective: To investigate the efficacy of the standard dose of Thymoglobuline® induction therapy for preventing acute rejection (AR) after transplantation among recipients of Donated after Cardiac Death (DCD) kidney…
- Trial name
- START-DCD (NCT03099122)
- Testing
- Rabbit Anti-thymocyte Immunoglobulin, Tacrolimus, Methylprednisolone
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Sanofi
Diabetes Mellitus
Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension
Primary Objective: To compare the metabolic and gastrointestinal pharmacodynamic (PD) effects of an 8 weeks treatment with sotagliflozin once daily (QD) to an 8 weeks treatment to empagliflozin QD in mild or moderate hypertensive…
- Trial name
- NCT03462069
- Testing
- Sotagliflozin (SAR439954), Empagliflozin
- Where
- Germany
- Volunteers
- 41 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.